Home » Topics » BioWorld Science

BioWorld Science
RSS

Jiangsu Aosaikang Pharmaceutical identifies H+/K+ ATPase inhibitors

Sep. 4, 2019

Phase II trial of AR-105 for ventilator-associated pneumonia does not meet primary endpoint

Sep. 4, 2019

Medshine Discovery divulges kynurenine production inhibitors

Sep. 4, 2019

Turning Point Therapeutics reports new data on repotrectinib and TPX-0046

Sep. 4, 2019

Positive preclinical data presented for Cocrystal Pharma's CC-42344

Sep. 4, 2019

Pfizer synthesizes new KRAS inhibitors

Sep. 4, 2019

Phase III AMPLIFY study of phosphate absorption inhibitor tenapanor meets primary endpoint

Sep. 4, 2019

Discovery of a first-in-class dual adenosine A2A/A2B receptor antagonist

Sep. 4, 2019

Machine learning from adversity speeds compound development

Sep. 4, 2019

Biogen explores non-covalent activation of NRF2 for neurodegenerative and other disorders

Sep. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...